



INVESTOR IN PEOPLE

The Patent Office
 Concept House
 Cardiff Road
 Newport
 South Wales
 NP10 8QQ

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
 COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 09 DEC 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

A. S. Jones

Dated 1 December 2004

Patents Form 1/77Patents Act 1977
(Rule 16)**The
Patent
Office**14NOV03 E852000-1 010176
P01/7700 0.00-0326486.8**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH1. Your reference **GBP290097**2. Patent application number
(The Patent Office will fill in this part)THE PATENT OFFICE
RM

14 NOV 2003

RECEIVED BY FAX

0326486.8

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Pharma Mar, S.A.U.,
Poligono Industrial La Mina
Avda. de los Reyes, 1
Colmenar Viejo
E-28770 Madrid
Spain

14 NOV 2003

Patents ADP number (if you know it)

8570863001 IS

If the applicant is a corporate body, give the country/state of its incorporation

Spain

4. Title of the invention **Combination Treatment**

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Marks & Clerk
66-68 Hills Road
Cambridge
CB2 1LA

Patents ADP number (if you know it)

18001

7271125003

IS

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months

Country

Priority application No
(if you know it)Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional, application or resulted from an entitlement dispute

Number of earlier application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Yes

(Answer "Yes" if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form 0
Description 13
Claim(s)
Abstract
Drawing(s)

RM -

10. If you are also filing any of the following, state how many against each item.

Priority documents
Translations of priority documents
Statement of inventorship and right to grant of a patent (Patents Form 7/77)
Request for preliminary examination and search (Patents Form 9/77)
Request for substantive examination (Patents Form 10/77)
Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

Harriet Allen

Date: 14 November 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Cambridge Office
01223 345520

gbp290097

Combination Treatment

The invention relates to a combination of treatments, more particularly a combination treatment for cancer.

FIELD OF THE INVENTION

The present invention is directed to the use of ecteinascidin 743 and more especially combination products containing this compound for cancer therapy, in particular to the use of ecteinascidin 743 in combination with another active drug for the treatment of cancer.

BACKGROUND OF THE INVENTION

Cancer comprises a group of malignant neoplasms that can be divided into two categories, carcinoma, comprising a majority of the cases observed in the clinics, and other less frequent cancers, which include leukemia, lymphoma, central nervous system tumors and sarcoma. Carcinomas have their origin in epithelial tissues while sarcomas develop from connective tissues and those structures that had their origin in mesoderm tissues. Sarcomas can affect, for instance, muscle or bone and occur in the bones, bladder, kidneys, liver, lung, parotid, spleen, etc.,

Cancer is invasive and tends to metastasise to new sites. It spreads directly into surrounding tissues and also may be disseminated through the lymphatic and circulatory systems.

Many treatments are available for cancer, including surgery and radiation for localised disease, and drugs. However, the efficacy of available treatments on many cancer types is limited, and new, improved forms of treatment showing clinical benefit are needed.

This is especially true for those patients presenting with advanced and/or metastatic disease. It is also true for patients relapsing with progressive disease after having been previously treated with established therapies for which further treatment with the same therapy is mostly ineffective due to acquisition of resistance or to limitations in administration of the therapies due to associated toxicities.

Chemotherapy plays a significant part in cancer treatment, as it is required for treatment of advanced cancers with distant metastasis and often helpful for tumor reduction before surgery, and many anti-cancer drugs have been developed based on various modes of action.

The most commonly used types of anticancer agents include: DNA-alkylating agents (for example, cyclophosphamide, ifosfamide), antimetabolites (for example, methotrexate, a folate antagonist, and 5-fluorouracil, a pyrimidine antagonist), microtubule disrupters (for example, vincristine, vinblastine, paclitaxel), DNA intercalators (for example, doxorubicin, daunomycin, cisplatin), and hormone therapy (for example, tamoxifen, flutamide). The ideal antineoplastic drug would kill cancer cells selectively, with a wide therapeutic index relative to its toxicity towards non-malignant cells. It would also retain its efficacy against malignant cells, ~~even after~~ prolonged exposure to the drug. Unfortunately, none of the current chemotherapies possess an ideal profile. Most possess very narrow therapeutic indexes and, in practically every instance, cancerous cells exposed to slightly sublethal concentrations of a chemotherapeutic agent will develop resistance to such an agent, and quite often cross-resistance to several other antineoplastic agents.

The ecteinascidins (herein abbreviated ETs) are exceedingly potent antitumor agents isolated from the marine tunicate *Ecteinascidia turbinata*. Several ecteinascidins have been reported previously in the patent and scientific literature. See, for example U.S. Pat. No. 5,089,273, which describes novel compositions of matter extracted from the tropical marine invertebrate, *Ecteinascidia turbinata*, and designated therein as ecteinascidins 729, 743, 745, 759A, 759B and 770. These compounds are useful as antibacterial and/or antitumor agents in mammals. U.S. Pat. No. 5,478,932 describes ecteinascidins isolated from the Caribbean tunicate *Ecteinascidia turbinata*, which provide *in vivo* protection against P388 lymphoma, B16 melanoma, M5076 ovarian sarcoma, Lewis lung carcinoma, and the LX-1 human lung and MX-1 human mammary carcinoma xenografts.

One of the ETs, ecteinascidin-743 (ET-743), is a novel tetrahydroisoquinoline alkaloid with considerable antitumor activity in murine and human tumors *in vitro* and *in vivo*, and is presently in clinical trials. ET-743 possesses potent antineoplastic activity against a variety of human tumor xenografts grown in athymic mice, including melanoma and ovarian and breast carcinoma.

A clinical development program of ET-743 in cancer patients was started with phase I studies investigating 1-hour, 3-hour, 24-hour and 72-hour intravenous infusion schedules and a 1 hour daily x 5 (dx5) schedule. Promising responses were observed in patients with sarcoma and breast and ovarian carcinoma. Therefore this new drug is currently under intense investigation in several phase II clinical trials in cancer patients with a variety of neoplastic diseases.

Further detail on the use of ET-743 for the treatment of the human body for cancer is given in WO 0069441, incorporated herein by reference in its entirety. At pages 8 and 9, this patent specification

indicates that ET-743 may be employed in a combination therapy with another drug. A list of candidates for the other drug is given, and mentions doxorubicin.

A recent review of ET-743, its chemistry, mechanism of action and preclinical and clinical development can be found in Kesteren, Ch. Van et al., 2003, *Anti-Cancer Drugs*, 14 (7), pages 487-502: "ET-743 (trabectedin, ET-743): the development of an anticancer agent of marine origin", and references therein.

Combination therapy using drugs with different mechanisms of action is an accepted method of treatment which helps prevent development of resistance by the treated tumor. *In vitro* activity of ET-743 in combination with other anticancer agents has been studied, see for example WO 02 36135, incorporated herein by reference in its entirety.

In particular, WO 0236135 mentions the combination of ET-743 with doxorubicin. A synergistic effect is noted in tests on animal models.

Meco *et al* report on "Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies" in *Cancer Chemother Pharmacol* (2003) 52: 131-138. The combination was tested against a sarcoma cell line and against mice with transplanted human sarcomas. They report an additive effect, and suggest that the combination might be effective for tumors displaying low sensitivity to each drug given alone.

It is an object of the invention to provide an efficacious combination treatment of cancer based on ET-743 with doxorubicin.

SUMMARY OF THE INVENTION


According to the present invention, we provide a combination therapy for the treatment of cancer which employs ecteinascidin 743 and doxorubicin, using a cyclical dosing protocol. Typical dosing protocols for the combination therapy are provided. From phase I clinical trials, we have determined that a combination of ET-743 and doxorubicin is tolerable and feasible, with evidence of antitumor activity.

We also provide a method of treating a cancer patient, which comprises administering ET-743 and doxorubicin. The ET-743 and doxorubicin are preferably administered on the same day of a predetermined cycle.

We further provide the use of ET-743 in the preparation of a medicament for carrying out the method of treatment. We also provide the use of the doxorubicin, in the preparation of a medicament for carrying out the method of treatment. We provide the use of ET-743 and the doxorubicin, in the preparation of a medicament for carrying out the method of treatment.

DETAILED DESCRIPTION

ET-743 is a natural compound represented by the following formula:



As used herein, the term "ET-743" also covers any pharmaceutically acceptable salt, ester, solvate, hydrate or a prodrug compound which, upon administration to the recipient is capable of providing (directly or indirectly) the compound ET-743. The preparation of salts and other derivatives, and prodrugs, can be carried out by methods known in the art.

ET-743 is typically supplied and stored as a sterile lyophilized product, with ET-743 and excipient in a formulation adequate for therapeutic use, in particular a formulation containing mannitol and a phosphate salt buffered to an adequate pH.

It is currently preferred to administer the ET-743 by infusion. The infusing step is typically repeated on a cyclic basis, which may be repeated as appropriate over for instance 1 to 20 cycles. The cycle includes a phase of infusing ET-743, and usually also a phase of not infusing ET-743. Typically the cycle is worked out in weeks, and thus the cycle normally comprises one or more weeks of an ET-743 infusion phase, and one or more weeks to complete the cycle. In one embodiment a cycle of 3 weeks is preferred. Alternatively it can be from 2 to 6 weeks. The infusion phase can itself be a single administration in each cycle of say 1 to 72 hours, more usually 1, 3 or 24 hours, or infusion on a daily basis in the infusion phase of the cycle for preferably

1 to 5 hours, especially 1 or 3 hours. Thus, for example, the ET-743 might be administered on each of the first five days of a 3 week cycle. We currently prefer a single administration at the start of each cycle.

The dose will be selected according to the dosing schedule, having regard to the existing data on Dose Limiting Toxicity, on which see for example the incorporated WO patent specifications, and also see Kesteren, Ch. Van *et al.*, 2003, *Anti-Cancer Drugs*, 14 (7), pages 487-502: "ET-743 (trabectedin, ET-743): The development of an anticancer agent of marine origin". This article is incorporated herein in full by specific reference.

For a single administration of ET-743 at the start of each cycle, we prefer a dose in the range 0.2 to 2 mg/m², more preferably 0.4 to 1.5 mg/m², most preferably 0.7 to 1.2 mg/m². For this combination we particularly prefer a dose from below 0.8 mg/m², more preferably from about 0.2 to about 0.775 mg/m², most preferably about 0.5 to about 0.75 mg/m². Particularly preferred is a range from about 0.6 to about 0.725 mg/m², in particular of about 0.7 mg/m².

As noted in the incorporated article by Kesteren, the combination of ET-743 with dexamethasone gives unexpected advantages. It has a role in hepatic prophylaxis. We therefore prefer to administer dexamethasone to the patient, typically at around the time of infusing the ET-743. For example, we prefer to give dexamethasone before ET-743 on the same day. The administration of dexamethasone can be extended, for example to one or more days preceding or following ET-743.

The ET-743 is administered as part of a combination therapy with doxorubicin.

Doxorubicin is indicated for the treatment of many cancers, including for instance breast cancer, ovarian cancer, transitional cell bladder cancer, bronchogenic lung cancer, thyroid cancer, gastric cancer, soft tissue and osteogenic sarcomas, neuroblastoma, Wilms' tumor, malignant lymphoma (Hodgkin's and non-Hodgkin's), acute myeloblastic leukemia, acute lymphoblastic leukemia, Kaposi's sarcoma related to acquired immunodeficiency syndrome (AIDS).

The doxorubicin is administered by intravenous push as part of the cycle of treating the patient. We prefer that the doxorubicin is given on the same day as ET-743, either before or after. An interval between the two drugs may be necessary, an interval of about 1 hour is preferred. For a cycle of 3 weeks, we prefer administration on day 1 with ET-743. Other administration protocols can be designed having regard to this embodiment.

The dosage amount of doxorubicin is preferably in the range from 30 to 100 mg/m²/day, more preferably 40 to 80 mg/m²/day. At this stage, we currently prefer a dose of about 50 mg/m²/day or about 60 mg/m²/day.

Depending on the type of tumor and the developmental stage of the disease, the treatments of the invention are useful in preventing the risk of developing tumors, in promoting tumor regression, in stopping tumor growth and/or in preventing metastasis. In particular, the method of the invention is suited for human patients, especially those who are relapsing or refractory to previous chemotherapy. First line therapy is also envisaged.

Preferably, the combination therapy is used according to the above schedules and dosages for the treatment of sarcoma, osteosarcoma, ovarian cancer, breast cancer, melanoma, colorectal

cancer, mesothelioma, renal cancer, endometrial cancer and lung cancer. Most preferably the patients are sarcoma patients, especially those with a soft tissue sarcoma.

In a further aspect of the present invention, a medical kit for administering ET-743 in combination with doxorubicin is provided, comprising printed instructions for administering ET-743 according to the dosing schedules set forth above, and a supply of ET-743 in dosage units for at least one cycle, wherein each dosage unit contains the appropriate amount of ET-743 for the treatments as defined above and a pharmaceutically acceptable carrier.

Although guidance for the dosage is given above, the correct dosage of the compound will vary according to the particular formulation, the mode of application, and the particular situs, host and tumor being treated. Other factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account. Administration can be carried out continuously or periodically within the maximum tolerated dose.

EXAMPLE: Phase I Clinical trial

The objective of this study was the definition of the least toxic sequence (LTS) and optimal therapeutic dose of ET-743 in combination with doxorubicin (doxo) in patients with untreated metastatic soft tissue sarcomas (STS) and advanced pre-treated anthracycline-naïve breast cancer patients (ABC).

ET-743 is a DNA minor groove binder selectively blocking transcription of activated genes which is active in patients (pts) with ovarian and breast cancer and is currently undergoing development in STS. In this

multicenter dose and LTS finding trial, pts were assigned consecutively to start either with sequence A (ET-743 before Doxo) or with the reverse sequence (B) every 21 days. Pharmacokinetic [PK] of both drugs was determined for the 2 sequences at cycle 1 and cycle 2, when patients received the drugs in the reverse order of administration. Alternating sequence was discontinued at observation of dose limiting toxicity [DLT]: observation of grade 4 hematological toxicity for more than 3 days at the entry level. Both drugs were administered on day 1, with a 1 h interval between the 2 drugs (ET-743, 3-hr infusion i.v. and Doxo, 1-hr infusion i.v push with steroids & 5 HT₃ antagonists as antiemetic prophylaxis). Oral steroids premedication for ET-743 was given 24 h before and for 48h following the day of treatment. Doxo was administered at the fixed dose of 60mg/m², while ET-743 was started at 600 µg/m² and escalated thereafter in subsequent cohorts of at least 3 new cases. Pts continued treatment until progressive disease (PD) or intolerance, and were restaged every 2 cycles for activity. Prior adjuvant therapy was permitted if recurrence ≥ 6 months from end and receiving maximum cumulative Doxo-equivalent dose ≤ 280 mg/m². Normal liver, hematologic and cardiac function were required.

In this study, 22 pts were enrolled and evaluable. No DLTs had been noted among the pts enrolled up to 700 µg/m². The dose was escalated to 800 µg/m² at which 4 DLTs, (2 in sequence A due to grade 4 absolute neutrophil count (ANC) > 7 days and febrile neutropenia, and the other 2 in sequence B with ANC grade 4 > 7 days + G3 asthenia and febrile neutropenia). Comparison of the plasma disposition of ET-743 and doxorubicin in patients receiving both sequences did not reveal any significant pharmacokinetic interaction.

Antitumor activity was observed: 5 pts had a confirmed partial response (PR) (2 at ET-743 dose level 600µg/m², 1 at ET-743 dose level 700µg/m² and 2 at ET-743 dose level 800µg/m²) and 5 a long lasting (> 6 months)

stable disease (SD) (2 at ET-743 dose level 600 μ g/m², 1 at ET-743 dose level 700 μ g/m² and 2 at ET-743 dose level 800 μ g/m²).

More information is as follows:

Statistical Design

Determination of Maximum Tolerated Dose (MTD) at least 2/6 pts with DLTs

Determination of Recommended Dose (RD) < 2 DLTs in 6 pts

Eligibility Criteria

Normal renal, liver, cardiac & hematological functions

PS \leq 1

Measurable disease (RECIST criteria).

STS or Breast histology

Prior chemotherapy:

< 1 Prior non-anthracycline CTx for ABC; adjuvant only for STS

Maximum prior doxo/doxo equivalent dose \leq 280mg/m²

Definition of DLT

Gr 4 ANC > 7days

G 4 platelets or Hb

G3 stomatitis \geq 3 days

Hepatic

Elevation of AlkPhos \geq G3

Elevation of bilirubin/transaminases/alk phos of any grade

w/out recovery by D28

Patients & Study Characteristics

Entered/Evaluable	23/22
Tumor type	
ABC	4
STS	18
Dose Level	
600 (all STS)	10 (6A/4B)
700 (all STS)	3 (1A/2B)
800 (5 STS/4ABC)	9 (6A/3B)
Sex M/F	3/19
P. Status-ECOG 0	91%
Prior therapy (2 cases)	1 STS pt @dose level 600 [6cycles epi- adj] 1 STS pt @ dose level 800 [6 cycles doxo-neoadj]

Dose Escalation

A		DOSE	B	
		No.		
No.	DLT		No.	DLT
6	0	600	4	0
		10		
1	0	700	2	0
		3		
6	2	800	3	2
		9		

Activity

PT #	PRIMARY TUMOR TYPE	ET-743 DOSE $\mu\text{g}/\text{m}^2$	SITES OF DISEASE	BEST RESP	TTP months
3	STS	600	LN, lung, bone	PR	2
9	STS-ovary	600	Abdo, skin	PR	5
5	STS	600	Pelvis, bone	SD	5+
10	STS	600	Lung	SD	5
13	STS	700	Lung, mediastinum, LN	PR	7+
11	STS-uterus	700	Lung	SD	6
15	STS-uterus (prior adjuvant doxo-6 cycles)	800	Abdomen, pelvis	PR	4
16	ABC	800	Pleura, chest wall, LN	PR	5+
18	STS-cervix	800	Lung	SD	6+
21	STS	800	Lung, subcutaneous	SD	4+

Conclusions

The MTD was defined by prolonged grade 4 neutropenia/febrile neutropenia at 800 $\mu\text{g}/\text{m}^2$ of ET-743 and 60 mg/m^2 of Doxo.

Grade 4 neutropenia at the entry level nullified the application of alternating sequence A and B in the same patients.

Toxicity was similar with both sequences and order of administration did not influence the pharmacokinetics of either drug.

Antitumor activity was observed at 700 $\mu\text{g}/\text{m}^2$ of ET-743 in combination with Doxo.